Showing 1 - 10 of 7,830
Price regulation and competition patterns in the ethical drug industry in france This article gives the results of an econometric modelization of the ethical drugs price and quantity determination institutionnal process for France. From price and promotion elasticities, it is shown that...
Persistent link: https://www.econbiz.de/10011096648
Le texte ci-dessous entend contribuer à enrichir le débat sur une des principales innovations qui aient été proposées ces dernières années pour le système de santé. Ce débat doit porter sur la pertinence du constat préalable, sur la logique du projet des Réseaux de Soins Coordonnés...
Persistent link: https://www.econbiz.de/10011096667
Persistent link: https://www.econbiz.de/10011105184
Persistent link: https://www.econbiz.de/10011105185
After generics, which are copies of chemical medicines, "copies" of already patented biologics (biosimilars) are entering the biologics market and competing with their originators. Many uncertainties remain regarding the development of this newly emerging market, and the ability of biosimilars...
Persistent link: https://www.econbiz.de/10011105187
Is, or should, healthcare be profitable? Over and above “private” health, does it have an effect on public health? Improved living conditions are sometimes considered to play a more important role in greater life expectancy than medicine. Even though this may have been true in the 19th...
Persistent link: https://www.econbiz.de/10011166327
Background : There are limited data available on the economical burden of psoriasis and its impact on everyday life. Objective : The aim of this study was to evaluate the impact of psoriasis on personal and professional life, and to evaluate the cost of psoriasis for the patient. Methods : We...
Persistent link: https://www.econbiz.de/10011166484
Persistent link: https://www.econbiz.de/10011166567
Persistent link: https://www.econbiz.de/10011166575
The recently published "Survival and Ventricular Enlargement" (SAVE), prospective controlled trial over 4 years including over 2,000 patients, has shown that long-term treatment with captopril reduced cardiovascular mortality (- 19%) and morbidity in patients with post-infarction left...
Persistent link: https://www.econbiz.de/10011265513